Inmolecule Nanotech (XPAR:MLINA) EBIT: € Mil (TTM As of Dec. 2024)


XPAR:MLINA Inmolecule Nanotech SA XPAR:MLINA
6 GF Score
Price €4.08
! 2 Warning Signs
View Full Analysis

What is Inmolecule Nanotech EBIT?

Inmolecule Nanotech XPAR:MLINA 6 EBIT is € Mil as of Dec. 2024. GuruFocus rates XPAR:MLINA with a GF Score™ of 6/100. The stock has 2 warning signs investors should review.

Inmolecule Nanotech's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2024 was €-0.22 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Inmolecule Nanotech's annualized ROC % for the quarter that ended in Dec. 2024 was -2.01%. Inmolecule Nanotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -6.46%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

Inmolecule Nanotech  (XPAR:MLINA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Inmolecule Nanotech's annualized ROC % for the quarter that ended in Dec. 2024 is calculated as:

ROC % (Q: Dec. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Dec. 2024 ))/ count )
=-0.218 * ( 1 - 0% )/( (12.109 + 9.592)/ 2 )
=-0.218/10.8505
=-2.01 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=14.42 - 2.251 - ( 0.06 - max(0, 3.134 - 7.523+0.06))
=12.109

Invested Capital(Q: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=12.303 - 2.624 - ( 0.087 - max(0, 2.908 - 6.081+0.087))
=9.592

Note: The Operating Income data used here is one times the annual (Dec. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Inmolecule Nanotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Dec. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-0.217/( ( (0.205 + max(4.233, 0)) + (0.307 + max(1.975, 0)) )/ 2 )
=-0.217/( ( 4.438 + 2.282 )/ 2 )
=-0.217/3.36
=-6.46 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2.209 + 2.727 + 2.426) - (2.251 + 0 + 0.878)
=4.233

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.127 + 2.46 + 1.291) - (2.624 + 0 + 0.279)
=1.975

When net working capital is negative, 0 is used.

Note: The EBIT data used here is one times the annual (Dec. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Inmolecule Nanotech's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2024 )
=/32.519
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inmolecule Nanotech EBIT Related Terms

Inmolecule Nanotech EBIT Historical Data

* Premium members only.

The historical data trend for Inmolecule Nanotech's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inmolecule Nanotech EBIT Chart

Inmolecule Nanotech Annual Data
Trend Dec23 Dec24
EBIT
-1.64 -0.22

Inmolecule Nanotech Semi-Annual Data
Dec23 Dec24
EBIT -1.64 -0.22

XPAR:MLINA vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Inmolecule Nanotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Inmolecule Nanotech EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inmolecule Nanotech's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Inmolecule Nanotech's EV-to-EBIT falls into.


XPAR:MLINA
6GF Score
Inmolecule Nanotech SA XPAR:MLINA
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Inmolecule Nanotech EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was € Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of € Mil mean?
Inmolecule Nanotech (XPAR:MLINA) has a EBIT of € Mil as of Dec. 2024. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Inmolecule Nanotech.
Is Inmolecule Nanotech's EBIT too high?
Inmolecule Nanotech's current EBIT is € Mil. Overall, Inmolecule Nanotech has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Inmolecule Nanotech's EBIT compare to VRTX and REGN?
Inmolecule Nanotech's EBIT of € Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Inmolecule Nanotech. Inmolecule Nanotech's current EBIT is € Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inmolecule Nanotech stock overvalued right now?
Inmolecule Nanotech (XPAR:MLINA) has a current EBIT of € Mil. The current EBIT is € Mil. Inmolecule Nanotech's overall GF Score™ is 6/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Inmolecule Nanotech (XPAR:MLINA), the current EBIT is € Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Inmolecule Nanotech Business Description

Address Paseo de la Castellana 91, 4th Floor, Madrid, ESP, 28046
Inmolecule Nanotech SA is a research and development company. The company provides health care, home care and personal care products.
6GF Score

Get the complete analysis for XPAR:MLINA

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.08
Price